Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 25 Mar 2026 for Tempest Therapeutics, Inc., €431k.
Filing timeline
BuySaleMatthew Angel
Insider track record
Disclosed buys
2
Disclosed sells
0
Signal history
No signal scores available.
Closed purchases
Market purchases
2
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -30.1%Entry US$1.66 · Close at T+90 US$1.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Matthew Angel: trading record in brief
All filings by Matthew Angel on record concern Tempest Therapeutics, Inc. Activity is concentrated on a single trading day, 24 March 2026, with 2 filings.
No open-market sale appears; the market trades are 2 purchases worth €862k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The newest entry dates from 23 June 2026: an open-market purchase of €431k, in Tempest Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Matthew Angel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations1 total
231,482 shares@ US$2.16100.0% of flowCommon StockSEC:0001931356-26-000011:0
Canonical exit: 22 Jun 2026 (T+90)
1 of 1 declaration
